Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (131-140 of 440) with videos related to

Pageof 44
Sort By:
Cancer Research|May 19, 2007
The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cellsYuanzheng Qiu, Xiangguo Liu, Wei Zou, et al.
The Journal of Biological Chemistry|March 26, 2010
Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradationChunyang Li, Shuzhen Chen, Ping Yue, et al.
The Journal of Biological Chemistry|June 28, 2020
Correction: Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IκBα degradationChunyang Li, Shuzhen Chen, Ping Yue, et al.
Oncotarget|August 4, 2016
Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylationShardule P Shah, Ajay K Nooka, David L Jaye, et al.
British Journal of Haematology|May 19, 2018
Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trialPaul G Richardson, Robert L Schlossman, Anuja N Roy, et al.
Journal of Oncology Practice|July 12, 2018
Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and ElotuzumabAjay K Nooka, Charise Gleason, Marva Ollivierre Sargeant, et al.
Expert Review of Clinical Pharmacology|October 28, 2015
Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomesPaul G Richardson, R Donald Harvey, Jacob P Laubach, et al.
Cancer Letters|July 31, 2018
Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacyGuoqing Qian, Weilong Yao, Shuo Zhang, et al.
The Journal of Biological Chemistry|December 25, 2007
Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529Sumin Kang, Shaozhong Dong, Ailan Guo, et al.
British Journal of Haematology|January 12, 2011
Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancersPaul G Richardson, Constantine S Mitsiades, Jacob P Laubach, et al.
Pageof 44

Showing results (131-140 of 440) with videos related to

Sort By:
Pageof 44
Cancer Research|May 19, 2007
The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cellsYuanzheng Qiu, Xiangguo Liu, Wei Zou, et al.
The Journal of Biological Chemistry|March 26, 2010
Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradationChunyang Li, Shuzhen Chen, Ping Yue, et al.
The Journal of Biological Chemistry|June 28, 2020
Correction: Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IκBα degradationChunyang Li, Shuzhen Chen, Ping Yue, et al.
Oncotarget|August 4, 2016
Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylationShardule P Shah, Ajay K Nooka, David L Jaye, et al.
British Journal of Haematology|May 19, 2018
Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trialPaul G Richardson, Robert L Schlossman, Anuja N Roy, et al.
Journal of Oncology Practice|July 12, 2018
Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and ElotuzumabAjay K Nooka, Charise Gleason, Marva Ollivierre Sargeant, et al.
Expert Review of Clinical Pharmacology|October 28, 2015
Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomesPaul G Richardson, R Donald Harvey, Jacob P Laubach, et al.
Cancer Letters|July 31, 2018
Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacyGuoqing Qian, Weilong Yao, Shuo Zhang, et al.
The Journal of Biological Chemistry|December 25, 2007
Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529Sumin Kang, Shaozhong Dong, Ailan Guo, et al.
British Journal of Haematology|January 12, 2011
Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancersPaul G Richardson, Constantine S Mitsiades, Jacob P Laubach, et al.
Pageof 44